This report was first published by Endpoints News. To see the original version, click here
GSK has offloaded a corporate venture unit that invests in bioelectronic startups working on neuromodulation, wearables, implanted devices and other technology, Endpoints News has learned.
The VC unit, Action Potential Venture Capital (APVC), launched with $50 million from GSK in 2013, when it made its first investment in SetPoint Medical, creator of an implantable device to assuage inflammatory diseases.
您已阅读21%（497字），剩余79%（1876字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。